Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
glucocorticoid receptor antagonist
|
| gptkbp:clinical_trial |
Phase 3
NC T01208001 NC T01208014 NC T01208027 NC T01208040 NC T01208053 hyperglycemia due to Cushing's syndrome |
| gptkbp:contraindication |
adrenal insufficiency
pregnancy |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
2012-02-17
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:has_ability |
300 mg
|
| https://www.w3.org/2000/01/rdf-schema#label |
Korlym
|
| gptkbp:ingredients |
mifepristone
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
2027-02-17
|
| gptkbp:is_used_for |
gptkb:Cushing's_syndrome
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
Corcept Therapeutics
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:population |
adults
patients with Cushing's syndrome |
| gptkbp:price |
varies by pharmacy
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved Health Canada approved |
| gptkbp:requires |
available online
prescription only |
| gptkbp:research_focus |
endocrine disorders
hormonal disorders Cushing's syndrome treatment |
| gptkbp:safety_features |
available on request
|
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:side_effect |
gptkb:fandom
anxiety dizziness fatigue headache nausea hypertension vomiting diarrhea insomnia hypokalemia edema |
| gptkbp:storage |
room temperature
|
| gptkbp:bfsParent |
gptkb:RU-486
|
| gptkbp:bfsLayer |
5
|